Interests in the use of Rapid Prostate Antigen Screening Test in the North-Cameroon

Authors

  • Herve Kada Pabame Department of Biomedical Sciences, Faculty of Science, University of Ngaoundere, Ngaoundere, Cameroon
  • Richard Tagne Simo Department of Biomedical Sciences, Faculty of Science, University of Ngaoundere, Ngaoundere, Cameroon
  • Armel Herve Nwabo Kamdje Department of Biomedical Sciences, Faculty of Science, University of Ngaoundere, Ngaoundere, Cameroon
  • Louis Deweerdt Centre Pasteur of Cameroon Annex of Garoua, Garoua, Cameroon
  • Guillaume Gayma Islamic clinic of Adamawa, Ngaoundere, Cameroon
  • Franklin Danki Sillong Islamic clinic of Adamawa, Ngaoundere, Cameroon

DOI:

https://doi.org/10.6000/1927-7229.2018.07.03.2

Keywords:

Cancer, prostate, Cameroon, PSA rate, RDT

Abstract

Introduction: The number of prostate cancer detected late because of the lack of means of investigation allowing a proximity screening, the poverty which characterize north are the two main elements which led us to lead this study which had for objective to shown the value of using rapid PSA screening tests.

Method: We conducted a cross-sectional analytical study in the city of Ngaoundere and Garoua for a period of 5 months.

Results: A total of 220 PSA level assays were performed over the 5-month period of our study with variations between the two selected centers. Of 30 samples used to study the sensitivity of rapid PSA screening tests, 22 were positive and 8 negative. The concordance rate for the positive values of the rapid test strip test versus the assay was 100%. The concordance of negative values was 87.5%. In addition, in a sample of 41 patients, PSA tests were performed in 30 patients, or 73.17%, and diagnosed prostate cancer in 69.23% of diagnosed cancer cases.

Conclusion: Rapid PSA screening tests are good tools for diagnosing prostate cancer when combined with other tools such as digital rectal examination and ultrasound.

References

Organisation mondial de la Santé. Maladies non transmissibles. Consulté à partir du site de l’Organisation mondiale de la Santé: http://www.who.int/topics/ noncommunicable_diseases/fr,2015.

Breslow N, Chan C, Dhom G, Drury R, Franks L, Gellei B, Lee Y, Lundberg S, Sparke B, et Sternbya N. Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France. International Journal of Cancer 1977; 20(5): 680-688. https://doi.org/10.1002/ijc.2910200506

Chauvet B, Villers A, Davin J-L, Nahon S. Actualités sur le dépistage, le diagnostic et le traitement des cancers de prostate. Bulletin du Cancer 2002; 89(1): 37-45.

Carroll P, Coley C, Mcleod D, Schellhammer P, Sweat G, Wasson J, Zietman A, et Thompson I. Prostate-specific antigen best practice policy—part I: early detection and diagnosis of prostate cancer. Urology 2001; 57(2): 217-224. https://doi.org/10.1016/S0090-4295(00)00993-6

D’Amico AV, Anthony V, Whittington R, Malkowicz S, Renshaw A, TomaszewskI J, Bentley C, Schultz D, Rocha S, Wein A, et Richie J-P. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology 2001; 58(3): 406-410. https://doi.org/10.1016/S0090-4295(01)01204-3

Villers A, Chautard D. PSA libre: l’utilisation en routine est prématurée pour le dépistage du cancer de la prostate. Progrès en Urologie 2000; 10(4): 618-21.

Catalona W, Partin A, Slawin K, Brawer M, Flanigan R, Patel A, Richie J-P, Walsh P, Scardino P, et Lange P. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279(19): 1542-1547. https://doi.org/10.1001/jama.279.19.1542

Ravery V, Javerliat I, Toublanc M, Boccon-Gibod L, Delmas V, Boccon-Gibod L. Caractéristiques des cancers prostatiques chez les français d’origine afro-antillaise. Progrès en Urologie 2000; 10(2): 231-236.

Catalona W, Richie J-P, Ahmann F, M’liss A, Scardino P, Flanigan R, Dekernion J, Ratliff L, Kavoussi L, et Dalkin L. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. The Journal of Urology 1994; 151(5): 1283-1290. https://doi.org/10.1016/S0022-5347(17)35233-3

Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. The Journal of Urology 2000; 164(2): 393-396. https://doi.org/10.1016/S0022-5347(05)67368-5

Baudin B. Les tests de diagnostic rapide en biochimie médicale: intérêts, limites et dangers. Revue Francophone des Laboratoires 2015; 2015(475): 31-38. https://doi.org/10.1016/S1773-035X(15)30247-1

Nkwenkeu SF. Evaluation des politiques publiques de santé: une analyse économique appliquée au Cameroun 2014.

Quatrième Enquête Camerounaise Auprès des Ménages (ECAM 4): Tendance, profil et déterminants de la pauvreté au Cameroun entre 2001-2014. Institut national de la statistique, déc-2015.

profil des pays pour le cancer. organisation mondiale de la santé, 2014.

Amiel J, Chevallier D, Peyrottes A, Benoliel J, Toubol J. Corrélations anatomoclinique et biologique (PSA-PAP) dans la pathologie prostatique: à propos de 150 observations. Journal d’urologie 1990; 96(4): 199-201.

Fulla Y, Noel M, Le Brun G. Optimisation de l’utilisation du PSA. Médecine Nucléaire 2008; 32(1): 31-40. https://doi.org/10.1016/j.mednuc.2007.11.004

Downloads

Published

2018-08-10

How to Cite

Herve Kada Pabame, Richard Tagne Simo, Armel Herve Nwabo Kamdje, Louis Deweerdt, Guillaume Gayma, & Franklin Danki Sillong. (2018). Interests in the use of Rapid Prostate Antigen Screening Test in the North-Cameroon . Journal of Analytical Oncology, 7(3), 43–46. https://doi.org/10.6000/1927-7229.2018.07.03.2

Issue

Section

Articles